SAN DIEGO, March 10, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that CEO and President Punit Dhillon will present a corporate overview at the 28th Annual ROTH Conference on Wednesday, March 16, 2016. The presentation is scheduled to begin at 8:00 AM PT at The Ritz Carlton, Orange County.
The 28th Annual ROTH Conference is one of the largest of its kind in the US with over 500 participating companies and over 3,000 attendees. The conference will feature presentations from hundreds of small and mid-cap public and private companies in a variety of sectors including: healthcare, technology, business services, and industrial growth. Over the course of the three-day event, there will be several panel discussions, one-on-one meetings, and 10 concurrent tracks of company presentations. For more information, please visit: http://www.roth.com/.
About OncoSec Medical Incorporated OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies for the treatment of cancer. The Company's investigational technology, ImmunoPulse™, is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as interleukin-12 (IL-12). In Phase I and II clinical trials, OncoSec's lead program, ImmunoPulse™ IL-12, demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. ImmunoPulse™ IL-12 is currently in Phase II development for several indications, including metastatic melanoma and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also seeking to identify and develop new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.
Contact: Mary Marolla OncoSec Medical Incorporated 855-662-6732 email@example.com
SOURCE OncoSec Medical Incorporated